相似文献
1
Biomarkers in cholangiocarcinoma.胆管癌中的生物标志物
Clin Liver Dis (Hoboken). 2014 May 27;3(5):101-103. doi: 10.1002/cld.345. eCollection 2014 May.
2
Circulating Biomarkers for Cholangiocarcinoma.胆管癌的循环生物标志物
Dig Dis. 2018;36(4):281-288. doi: 10.1159/000488342. Epub 2018 May 15.
3
Biomarkers and molecular biology targeting cholangiocarcinoma.针对胆管癌的生物标志物与分子生物学
Asian Pac J Cancer Prev. 2012;13 Suppl:1-2.
4
Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis.原发性硬化性胆管炎胆管癌生物标志物研究的最新进展。
Clin Res Hepatol Gastroenterol. 2019 Jun;43(3):236-243. doi: 10.1016/j.clinre.2018.08.013. Epub 2018 Sep 25.
5
Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis.肝内胆管癌：诊断和预后的分子标志物
Surg Oncol. 2017 Jun;26(2):125-137. doi: 10.1016/j.suronc.2016.12.009. Epub 2017 Feb 20.
6
Current omics-based biomarkers for cholangiocarcinoma.基于组学的胆管癌生物标志物。
Expert Rev Mol Diagn. 2019 Nov;19(11):997-1005. doi: 10.1080/14737159.2019.1673162. Epub 2019 Oct 1.
7
Analysis of new biomarkers for cholangiocarcinoma.胆管癌新生物标志物的分析
J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):397-8. doi: 10.1002/jhbp.69. Epub 2014 Jan 21.
8
Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma.微小RNA作为胆管癌生物标志物的诊断价值
Dig Liver Dis. 2016 Oct;48(10):1227-32. doi: 10.1016/j.dld.2016.07.006. Epub 2016 Jul 18.
9
A comparative proteomic analysis of bile for biomarkers of cholangiocarcinoma.胆管癌生物标志物的胆汁蛋白质组比较分析
Tumour Biol. 2017 Jun;39(6):1010428317705764. doi: 10.1177/1010428317705764.
10
Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma.胆汁和尿液肽标志物谱：胆管癌分子途径和生物学过程的关键入口。
J Biomed Sci. 2020 Jan 3;27(1):13. doi: 10.1186/s12929-019-0599-5.
引用本文的文献
1
Predicting cholangiocarcinoma in primary sclerosing cholangitis: using artificial intelligence, clinical and laboratory data.预测原发性硬化性胆管炎中的胆管癌：使用人工智能、临床和实验室数据。
BMC Gastroenterol. 2023 Apr 19;23(1):129. doi: 10.1186/s12876-023-02759-7.
2
Translational Proteomic Approach for Cholangiocarcinoma Biomarker Discovery, Validation, and Multiplex Assay Development: A Pilot Study.用于胆管癌生物标志物发现、验证和多重分析开发的转化蛋白质组学方法：一项初步研究。
Molecules. 2022 Sep 11;27(18):5904. doi: 10.3390/molecules27185904.
3
The Impact of Pre-analytical Quality Initiatives on Cholangiocarcinoma Diagnostics in Thailand.泰国前分析质量倡议对胆管癌诊断的影响。
Front Public Health. 2022 Jun 10;10:792847. doi: 10.3389/fpubh.2022.792847. eCollection 2022.
4
Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma.血清Dickkopf-1联合CA 19-9作为肝内胆管癌的生物标志物
Cancers (Basel). 2021 Apr 12;13(8):1828. doi: 10.3390/cancers13081828.
5
BIRC7 and STC2 Expression Are Associated With Tumorigenesis and Poor Outcome in Extrahepatic Cholangiocarcinoma.BIRC7 和 STC2 的表达与肝外胆管癌的肿瘤发生和不良预后相关。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820971676. doi: 10.1177/1533033820971676.
6
Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.血清无细胞 DNA 甲基化 OPCML 和 HOXD9 作为一种生物标志物，可能有助于胆管癌和其他胆道疾病的鉴别诊断。
Clin Epigenetics. 2019 Mar 4;11(1):39. doi: 10.1186/s13148-019-0634-0.
7
Automated selection of aptamers against cholangiocarcinoma cells on an integrated microfluidic platform.在集成微流控平台上自动筛选抗胆管癌细胞的适配体
Biomicrofluidics. 2017 Jul 5;11(4):044101. doi: 10.1063/1.4991005. eCollection 2017 Jul.
8
Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging?肝细胞癌和胆管癌的筛查：生物标志物能否取代影像学检查？
Curr Hepatol Rep. 2015 Jun;14(2):128-138. doi: 10.1007/s11901-015-0261-y.
本文引用的文献
1
Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis.荧光原位杂交在原发性硬化性胆管炎中胆管癌诊断中的应用：系统评价和荟萃分析。
Gastrointest Endosc. 2014 Jun;79(6):943-950.e3. doi: 10.1016/j.gie.2013.11.001. Epub 2013 Dec 19.
2
Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis.切除后胆管癌患者的预后生物标志物：系统评价和荟萃分析。
Ann Surg Oncol. 2014 Feb;21(2):487-500. doi: 10.1245/s10434-013-3286-x. Epub 2013 Oct 1.
3
Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy.原发性硬化性胆管炎伴细胞学不明确：荧光原位杂交和血清 CA 19-9 可预测恶性肿瘤风险。
Cancer Cytopathol. 2013 Dec;121(12):708-17. doi: 10.1002/cncy.21331. Epub 2013 Jul 9.
4
Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma.肝内胆管癌和肝细胞癌血清肿瘤标志物的比较。
Am Surg. 2010 Nov;76(11):1210-3.
5
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis.原发性硬化性胆管炎中荧光原位杂交检测阳性的长期结果。
Hepatology. 2010 Jan;51(1):174-80. doi: 10.1002/hep.23277.
6
Serum and bile biomarkers for cholangiocarcinoma.胆管癌的血清和胆汁生物标志物。
Curr Opin Gastroenterol. 2009 May;25(3):279-84. doi: 10.1097/mog.0b013e328325a894.
7
Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.血清细胞角蛋白19片段（CYFRA 21-1）作为原发性肝癌的标志物
Br J Cancer. 2003 Jun 16;88(12):1894-9. doi: 10.1038/sj.bjc.6601026.
8
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.CA 19-9在无原发性硬化性胆管炎患者胆管癌诊断中的应用
Am J Gastroenterol. 2000 Jan;95(1):204-7. doi: 10.1111/j.1572-0241.2000.01685.x.
Zotero 插件